Valsartan mess to spawn the latest surge of drug injury lawsuits: Bloomberg

lawsuit and book
One attorney predicted plaintiffs will file thousands of lawsuits over valsartan impurities. (Getty/eccolo74)

As the FDA and other drug agencies work to limit damage from a massive recall of blood pressure drugs, litigation stemming from the mess is just getting started.

Lawsuits have started to pile up alleging that tainted versions of valsartan harmed patients. But one lawyer involved says he expects thousands of personal injury lawsuits over the impurities—which turned up in versions of valsartan and its rival meds irbesartan and losartan—in the next two years.

At a status conference last month, attorney Daniel Nigh told judges he expects some 2,000 lawsuits claiming injuries from the adulterated drugs, all within the next two years, Bloomberg reports. So far, since the FDA initiated the first valsartan recall last year, plaintiffs have filed dozens of suits, the news service reports.

The sartan drug fiasco began last year when a U.S. drug manufacturer told the FDA it had discovered the impurity N-nitrosodimethylamine (NDMA) in a valsartan active pharmaceutical ingredient made by China’s Zhejiang Huahai Pharmaceutical. After investigating, the agency found NDMA and a similar chemical, NDEA, had contaminated certain valsartan APIs for years. The agency said the two contaminants, both considered probable carcinogens, can form through a specific and commonly used manufacturing process. 

The findings set off recalls around the world for blood pressure meds valsartan, irbesartan and losartan. The FDA kicked off a probe into the cause of the regulatory slip-up and its associated dangers to consumers. 

In January, the FDA said "overall, the risk to individual patients remains very small," but acknowledged it was still concerned about the episode.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

So far, plaintiffs have sued 40 companies, alleging they were harmed by the tainted drugs, Bloomberg reports. Defendants include Zhejiang, generics giants Teva and Mylan and numerous India-based generic drug makers.

In a letter to the judge overseeing the litigation, defense attorneys wrote that NDMA and NDEA are “organic chemicals that are the by-product of several biological and industrial processes.” They appear in air, water, soil, beer, cheese and other substances, the attorneys say, and don’t harm patients if they appear in drugs at trace levels.  

The defendants contend there’s “no evidence that the trace amount” of NDMA and NDEA found in drugs can cause cancer.

Suggested Articles

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.